Maxime Dely: Apheresis and the Limits of Standardization in Healthcare Quality
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Apheresis: how can we talk about quality when the patient is part of the process?
In hospitals, quality is built on solid foundations: validated protocols, controlled machines, and monitored indicators.
But in apheresis, one key element cannot be fully standardized: the patient.
In apheresis, the patient is not just the recipient of care.
They are part of the therapeutic process.
Same protocol, same team, same machine.
And yet, every session is different.
Tolerance, clinical condition, venous access, disease progression… variability is constant.
For hospital teams and blood bank organizations, this raises a fundamental question:
How do we ensure high quality in a living, adaptive process?
Of course, we rely on:
- Procedures
- Technical controls
- Traceability
But real quality is also built through:
- Adapting to the patient
- Managing clinical deviations
- Ensuring the safety of repeated sessions
In apheresis, quality is not only about compliance.
It is a balance between safety, effectiveness, and clinical reality.
How far can we standardize without losing the quality of care?”

Other posts featuring Maxime Dely on Hemostasis Today.
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
-
Nov 18, 2026, 13:25Maia Meier: Advocating for Women and Girls with Bleeding Disorders
-
Nov 18, 2026, 13:19Sjoerd Fabian Koopman: Exploring Tissue Distribution of Extended Half-Life Factor IX Concentrates